Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ESC 2026
Acoramidis improves health-related quality of life in wild-type and variant transthyretin amyloid cardiomyopathy: An EQ-5D-5L subgroup analysis from ATTRibute-CM
To evaluate the effect of acoramidis on HRQoL in participants with ATTRwt-CM and ATTRv-CM in the phase 3 ATTRibute-CM study.
Treatment with acoramidis resulted in significant and clinically meaningful benefits versus placebo in HRQoL in both ATTRwt-CM and ATTRv-CM.
Acoramidis provided a notably large magnitude of benefit versus placebo in ATTRv-CM, which may reflect the high HRQoL burden in this subgroup.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
